Literature DB >> 27932664

Adjusting for bias in unblinded randomized controlled trials.

A F Schmidt1, Rhh Groenwold2.   

Abstract

It may not always be possible to blind participants of a randomized controlled trial for treatment allocation. As a result, estimators of the actual treatment effect may be biased. In this paper, we will extend a novel method, originally introduced in genetic research, for instrumental variable meta-analysis, adjusting for bias due to unblinding of trial participants. Using simulation studies, this novel method, "Egger Correction for non-Adherence", is introduced and compared to the performance of the "intention-to-treat," "as-treated," and conventional "instrumental variable" estimators. Scenarios considered (time-varying) non-adherence, confounding, and between-study heterogeneity. The effect of treatment on a binary endpoint was quantified by means of a risk difference. In all scenarios with unblinded treatment allocation, the Egger Correction for non-Adherence method was the least biased estimator. However, unless the variation in adherence was relatively large, precision was lacking, and power did not surpass 0.50. As a comparison, in a meta-analysis of blinded randomized controlled trials, power of the conventional IV estimator was 1.00 versus at most 0.14 for the Egger Correction for non-Adherence estimator. Due to this lack of precision and power, we suggest to use this method mainly as a sensitivity analysis.

Entities:  

Keywords:  Monte Carlo method; Statistics; bias; instrumental variable; randomized controlled trials; treatment effectiveness

Mesh:

Year:  2016        PMID: 27932664     DOI: 10.1177/0962280216680652

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  2 in total

Review 1.  Meta-analysis and Mendelian randomization: A review.

Authors:  Jack Bowden; Michael V Holmes
Journal:  Res Synth Methods       Date:  2019-04-23       Impact factor: 5.273

2.  Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.

Authors:  Aroon D Hingorani; Chris Finan; Amand F Schmidt; Nicholas B Hunt; Maria Gordillo-Marañón; Pimphen Charoen; Fotios Drenos; Mika Kivimaki; Deborah A Lawlor; Claudia Giambartolomei; Olia Papacosta; Nishi Chaturvedi; Joshua C Bis; Christopher J O'Donnell; Goya Wannamethee; Andrew Wong; Jackie F Price; Alun D Hughes; Tom R Gaunt; Nora Franceschini; Dennis O Mook-Kanamori; Magdalena Zwierzyna; Reecha Sofat
Journal:  Nat Commun       Date:  2021-09-24       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.